Format

Send to

Choose Destination
Am J Surg. 2010 Jun;199(6):804-16. doi: 10.1016/j.amjsurg.2009.08.045. Epub 2010 Mar 15.

Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.

Author information

1
VA Boston Healthcare System and Boston University, 1400 VFW Pkwy., Boston, MA 02132, USA. kitani@va.gov

Abstract

BACKGROUND:

This open-label study compared oral or intravenous linezolid with intravenous vancomycin for treatment of complicated skin and soft-tissue infections (cSSTIs) caused by methicillin-resistant Staphylococcus aureus (MRSA).

METHODS:

Patients with proven MRSA cSSTI were randomized to receive linezolid or vancomycin. Clinical and microbiologic outcomes, duration of antimicrobial therapy, length of hospital stay, and safety were assessed.

RESULTS:

In the per-protocol population, the rate of clinical success was similar in linezolid- and vancomycin-treated patients (P = .249). The rate of success was significantly higher in linezolid-treated patients in the modified intent-to-treat population (P = .048). The microbiologic success rate was higher for linezolid at the end of treatment (P < .001) and was similar at the end of the study (P = .127). Patients receiving linezolid had a significantly shorter length of stay and duration of intravenous therapy than patients receiving vancomycin. Both agents were well tolerated. Adverse events were similar to each drug's established safety profile.

CONCLUSIONS:

Linezolid is an effective alternative to vancomycin for the treatment of cSSTI caused by MRSA.

PMID:
20227056
DOI:
10.1016/j.amjsurg.2009.08.045
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center